Search details
1.
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Invest New Drugs
; 41(3): 421-430, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37074571
2.
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol
; 158(3): 631-639, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32534811
3.
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Breast Cancer Res Treat
; 167(3): 671-686, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29063313
4.
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer.
Clin Adv Hematol Oncol
; 21(3): 125-127, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36867554
5.
New approaches to endocrine therapy in ER-positive, HER2-negative breast cancer.
Clin Adv Hematol Oncol
; 20(6): 356-358, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35731605
6.
CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.
J Natl Compr Canc Netw
; 13(8): 1005-11, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-26285246
7.
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol
; : JCO2301909, 2024 Apr 23.
Article
in English
| MEDLINE | ID: mdl-38652877
8.
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
J Clin Oncol
; 42(9): 987-993, 2024 Mar 20.
Article
in English
| MEDLINE | ID: mdl-38194616
9.
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Cancer Discov
; 14(2): 240-257, 2024 Feb 08.
Article
in English
| MEDLINE | ID: mdl-37916956
10.
Prevalence and impact of correlative science in breast cancer phase II trials.
Breast Cancer Res Treat
; 139(3): 845-50, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23771715
11.
Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer.
Clin Cancer Res
; 2023 Oct 27.
Article
in English
| MEDLINE | ID: mdl-37889120
12.
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Mol Cancer Ther
; 22(10): 1154-1165, 2023 10 02.
Article
in English
| MEDLINE | ID: mdl-37486983
13.
The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage.
Cancer Discov
; 12(7): 1620-1624, 2022 07 06.
Article
in English
| MEDLINE | ID: mdl-35791692
14.
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Clin Cancer Res
; 28(1): 36-44, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34645648
15.
Safety of bevacizumab in patients with metastatic breast cancer.
Oncology
; 80(5-6): 314-25, 2011.
Article
in English
| MEDLINE | ID: mdl-21778772
16.
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.
JAMA Oncol
; 7(12): 1873-1881, 2021 Dec 01.
Article
in English
| MEDLINE | ID: mdl-34647966
17.
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Clin Breast Cancer
; 21(6): 539-551, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34154926
18.
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.
JCO Precis Oncol
; 5: 1297-1311, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34994634
19.
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.
Mol Cancer Ther
; 20(8): 1442-1453, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34045233
20.
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Mol Cancer Ther
; 20(10): 1988-1995, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34315767